Half-year report · Q2
4564.TEDINET S100UOSE
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥356m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥695m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥708m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥709m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥548m | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥514m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥935m | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥528m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥881m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥880m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥677m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.42 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥183m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥109m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥537,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥387,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥403m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥357m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥512m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 411
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |